A reduction in the CD4+/CD8+ ratio is common in lung cancer patients after chemotherapy cycles, indicating an inhibition of the immune function in which the immune system's ability to recognise and kill mutant cells is weakening, leading to tumour growth and metastasis. This evidence concerns the gene CD8A and lung carcinoma.